5636-52-2

Usage

Uses

Used in Chemical Synthesis:
4-(2-DIMETHYLAMINO-ETHYL)-ANILINE is used as a precursor in the chemical synthesis industry for its ability to modify the properties of dyes and pigments, enhancing their color intensity and stability.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 4-(2-DIMETHYLAMINO-ETHYL)-ANILINE is used as a building block for the development of new drugs, contributing to the creation of innovative medicinal compounds.
Used in Agrochemicals:
4-(2-DIMETHYLAMINO-ETHYL)-ANILINE is utilized in the agrochemical sector as a starting material for the synthesis of various agrochemical products, such as pesticides and herbicides, due to its reactivity and potential to improve their effectiveness.
Used in Scientific Research:
4-(2-DIMETHYLAMINO-ETHYL)-ANILINE is employed in scientific research as a reagent or intermediate in the synthesis of complex organic molecules, facilitating the discovery of new chemical entities and understanding of chemical reactions.
It is crucial to handle 4-(2-DIMETHYLAMINO-ETHYL)-ANILINE with care, considering its potential health and environmental risks if mismanaged. Proper safety measures and disposal methods should be implemented to mitigate any adverse effects.

InChI:InChI=1/C10H16N2/c1-12(2)10-5-3-9(4-6-10)7-8-11/h3-6H,7-8,11H2,1-2H3

Upstream product

• 90405-67-7 N,N-dimethyl-2-(4-nitrophenyl)acetamide 
• 5339-05-9 N,N-dimethyl-2-(4-nitrophenyl)ethanamine 
• 81709-36-6 2-(4-Aminophenyl)N,N-dimethylacetamide 
• 861643-06-3 N,N-dimethyl-2-(4-nitrophenyl)ethanethioamide 
• 3544-25-0 p-aminophenylacetonitrile 
• 124-40-3 dimethyl amine 
• 13472-00-9 p-Aminophenethylamine 
• 616-38-6 carbonic acid dimethyl ester 
• 50434-36-1 4-nitrophenylacetyl chloride 
• 104-03-0 4-nitrobenzeneacetic acid 
• 5339-26-4 (4-nitrophenyl)ethyl bromide 
• 506-59-2 N,N-dimethylammonium chloride 
• 555-16-8 4-nitrobenzaldehdye 
• 51738-10-4 2,2-dibromo-1-(4-nitrophenyl)ethene 

Downstream Products

• 100880-15-7 {4-[bis-(2-chloro-ethyl)-amino]-phenethyl}-dimethyl-amine 
• 1027356-81-5 C₂₉H₃₁N₅O₃ 
• 1245500-46-2 C₂₅H₂₃N₇O₂S 
• 925242-34-8 C₂₁H₂₀ClFN₆S 
• 1190379-43-1 cyclobutanecarboxylic acid (3-{5-cyclopropyl-2-[4-(2-dimethylamino-ethyl)-phenylamino]-pyrimidin-4-ylamino}-propyl)-amide 

Relevant academic research and scientific papers

WEE1 inhibitors as well as preparation and application thereof

The invention relates to WEE1 inhibitors as well as preparation and application thereof. The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, and their use in the preparation of medicaments for the treatment of diseases associated with WEE1 activity.

WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME

A compound, or a pharmaceutically acceptable salts or prodrugs thereof, having the chemical structure (I) and methods of using these compounds to inhibit WEE1 kinase and treat cancer in a subject.

Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy

WEE1 kinase regulates the G2/M cell-cycle checkpoint, a critical mechanism for DNA repair in cancer cells that can confer resistance to DNA-damaging agents. We previously reported a series of pyrazolopyrimidinones based on AZD1775, a known WEE1 inhibitor, as an initial investigation into the structural requirements for WEE1 inhibition. Our lead inhibitor demonstrated WEE1 inhibition in the same nanomolar range as AZD1775, and potentiated the effects of cisplatin in medulloblastoma cells, but had reduced single-agent cytotoxicity. These results prompted the development of a more comprehensive series of WEE1 inhibitors. Herein we report a series of pyrazolopyrimidinones and identify a more potent WEE1 inhibitor than AZD1775 and additional compounds that demonstrate that WEE1 inhibition can be achieved with reduced single-agent cytotoxicity. These studies support that WEE1 inhibition can be uncoupled from the potent cytotoxic effects observed with AZD1775, and this may have important ramifications in the clinical setting where WEE1 inhibitors are used as chemosensitizers for DNA-targeted chemotherapy.

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

Synthesis and biological evaluation of new 4β-anilino-4′-O- demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

A series of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4β position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route.

IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION

Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula (I).

PYRIMIDINE INHIBITORS OF KINASE ACTIVITY

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.

2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND

A compound represented bv the formula [I]: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents -N-, -CH-, et al; Y1 represents a single bond, C1-3 alkylene, et al; Y2 represents C1-4 alkylene, oxy(C1-4 alkylene), et al; Ar1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar2 represents a 5- or 6-membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.

QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS

Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.